Lead cancer researcher elected to Academy of Medical Sciences
Today (8 May 2019) Dr Peter Campbell, Head of the Wellcome Sanger Institute's Cancer, Ageing and Somatic Mutation programme, joins 49 of the UK’s leading figures within biomedical and health sciences in becoming a Fellow of the Academy of Medical Sciences. The award honours scientists whose research has advanced medical science, delivered cutting-edge research discoveries, and produced benefits for patients and wider society. Many of the new Fellows have also contributed to medical science through outstanding leadership, public engagement and supporting the career advancement of junior trainees.
“I am delighted to become a Fellow of the Academy of Medical Sciences, it is a great honour to be recognised in this way. However, this award really belongs to my colleagues and collaborators here at the Sanger Institute and worldwide. Cancer is a massively complex interplay of genetic interactions that requires large-scale collaboration across to continents to investigate and analyse. I am grateful to everyone I have worked with over the years, and hope that our work will lay the foundations of understanding that will deliver improved treatment and prevention of this terrible disease.”
During his time at the Sanger Institute, Peter has been instrumental in developing new ways to explore and understand the processes that cause the development of cancer. His team's research into the key genetic mechanisms that drive cancer formation is having a profound impact on the field of cancer genomics and is opening up new clinical approaches to diagnosing and treating tumours.
“Peter is a tireless, visionary and generous researcher who is dedicated to unlocking the secrets of cancer and understanding the wider implications of somatic mutations in human cells. His leadership and insights have helped to produce new ways of understanding cancer formation that are laying the foundations for future discoveries and therapies that will be developed by researchers worldwide for years to come. His election to the Academy of Medical Sciences is extremely well deserved.”
Professor Sir Mike Stratton, Director of the Wellcome Sanger Institute
The Institute's cancer research programme is pioneering the use of cutting-edge DNA sequencing, cell biology and machine learning to create innovative methods to enhance clinical practice. For example, Peter and his team have developed a disease-prediction tool that can give personalised predictions of future disease outcomes for patients with certain types of blood cancers. While his role in helping to lead the work of the International Cancer Genome Consortium has been vital in coordinating researchers' efforts worldwide to develop a coherent and fine-grained understanding of the genetic roots of cancer.
“The Academy’s Fellowship is a unique assembly of the finest minds in biomedical and health research, from across the UK and beyond. Our Fellows are at the centre of all that we do, from supporting early career researchers via our hugely popular mentorship programme to incorporating public and patient views into health research. Their collective wisdom is a national asset to guide research and policy aimed at tackling pressing health challenges.
“It brings me great pleasure to congratulate the new Fellows, each of whom has pushed the boundaries of their individual research field. I am always delighted to see the Fellowship expand, adding fresh talent to our invaluable pool of high quality guidance, advice and expertise.”
Professor Sir Robert Lechler PMedSci, President of the Academy of Medical Sciences
Peter will be formally admitted to the Academy at a ceremony on 26 June 2019.